- Effect of direct-acting antivirals for hepatitis C virus-related hepatocellular carcinoma recurrence and death after curative treatment
-
Ahn YH, Lee H, Han JE, Cho HJ, Cheong JY, Park B, Kim SS
- KMID: 2534239
- J Liver Cancer.
- 2022 Sep;22(2):125-135.
- doi: 10.17998/jlc.2022.05.24
Background/Aim: There has been a long-standing debate about the association of directacting antiviral (DAA) therapy and hepatocellular carcinoma (HCC) recurrence. This study aimed to investigate the association between DAA therapy... -
- CITED
-
- Close
- SHARE
-
- Close
- The impact of unrestricted access to direct-acting antiviral among incarcerated hepatitis C virus-infected patients
-
Wong YJ, Thurairajah PH, Kumar R, Fock KM, Law NM, Chong SY, Manejero FG, Ang TL, Teo EK, Tan J
- KMID: 2517631
- Clin Mol Hepatol.
- 2021 Jul;27(3):474-485.
- doi: 10.3350/cmh.2021.0015
Background/Aims: Despite the disproportionally high prevalence rates of hepatitis C virus (HCV) amongst the incarcerated population, eradication remains challenging due to logistic and financial barriers. Although treatment prioritization based on... -
- CITED
-
- Close
- SHARE
-
- Close
- The predictors of sustained virological response with sofosbuvir and ribavirin in patients with chronic hepatitis C genotype 2
-
Han SY, Woo HY, Heo J, Park SG, Pyeon SI, Park YJ, Kim DU, Kim GH, Kim HH, Song GA, Cho M
- KMID: 2515686
- Korean J Intern Med.
- 2021 May;36(3):544-556.
- doi: 10.3904/kjim.2018.329
Background/Aims: Real-world, clinical practice data are lacking about sofosbuvir/ ribavirin (SOF/RBV) treatment of Korean patients with hepatitis C virus genotype 2 (HCV GT2) infection. This study investigated the efficacy and... -
- CITED
-
- Close
- SHARE
-
- Close
- Comorbidities and Prescribed Medications in Korean Patients with Chronic Hepatitis C: A Nationwide, Population-Based Study
-
Chung JW, Choi HY, Ki M, Jang ES, Jeong SH
- KMID: 2513702
- Gut Liver.
- 2021 Mar;15(2):295-306.
- doi: 10.5009/gnl19387
Background/Aims: Extrahepatic comorbidities and comedication are important to consider in the treatment of chronic hepatitis C (CHC) patients with direct-acting antivirals (DAAs) due to the risk of drug-drug interaction (DDI)... -
- CITED
-
- Close
- SHARE
-
- Close
- Comedications and potential drug-drug interactions with direct-acting antivirals in hepatitis C patients on hemodialysis
-
Hsu PY, Wei YJ, Lee JJ, Niu SW, Huang JC, Hsu CT, Jang TY, Yeh ML, Huang CI, Liang PC, Lin YH, Hsieh MY, Hsieh MH, Chen SC, Dai CY, Lin ZY, Chen SC, Huang JF, Chang JM, Hwang SJ, Chuang WL, Huang CF, Chiu YW, Yu ML
- KMID: 2511467
- Clin Mol Hepatol.
- 2021 Jan;27(1):186-196.
- doi: 10.3350/cmh.2020.0180
Background/Aims: Direct‐acting antivirals (DAAs) have been approved for hepatitis C virus (HCV) treatment in patients with end-stage renal disease (ESRD) on hemodialysis. Nevertheless, the complicated comedications and their potential drug-drug... -
- CITED
-
- Close
- SHARE
-
- Close
- Outcomes of Hepatitis C Virus Treatment with Ledipasvir/Sofosbuvir in Mongolian Population: Successes and Challenges Facing Scale-up of Care
-
Kang SH, Kim MY
- KMID: 2511458
- Clin Mol Hepatol.
- 2021 Jan;27(1):100-102.
- doi: 10.3350/cmh.2020.0312
-
- CITED
-
- Close
- SHARE
-
- Close
- Elimination of hepatitis C: What would be the practical approach?
-
Yim HJ
- KMID: 2511457
- Clin Mol Hepatol.
- 2021 Jan;27(1):97-99.
- doi: 10.3350/cmh.2020.0304
-
- CITED
-
- Close
- SHARE
-
- Close
- Efficacy and safety of ledipasvir/sofosbuvir in 5,028 Mongolian patients infected with genotype 1 hepatitis C virus: A multicenter study
-
Baatarkhuu O, Lee JS, Amarsanaa J, Kim DY, Ahn SH, Naranzul N, Enkhtuya D, Choijamts N, Batbayar P, Otgonbayar R, Saruul BU, Gantuul C, Gegeebadrakh B, Tuvshinbayar N, Badamsuren D, Ulzmaa G, Otgonbold J, Han KH
- KMID: 2511462
- Clin Mol Hepatol.
- 2021 Jan;27(1):125-135.
- doi: 10.3350/cmh.2020.0023
Background/Aims: Ledipasvir/sofosbuvir (LDV/SOF) shows high efficacy and safety in patients with genotype 1-hepatitis C virus (HCV). We aimed to investigate the efficacy and safety of LDV/SOF in real-world Mongolian patients. Methods:... -
- CITED
-
- Close
- SHARE
-
- Close
- A Survey of the Knowledge of and Testing Rate for Hepatitis C in the General Population in South Korea
-
Choi GH, Jang ES, Kim JW, Jeong SH
- KMID: 2508699
- Gut Liver.
- 2020 Nov;14(6):808-816.
- doi: 10.5009/gnl19296
Background/Aims: To eliminate hepatitis C virus (HCV) infection, improving public knowledge of and access to HCV screening and treatment is essential. The aim of this study was to evaluate the... -
- CITED
-
- Close
- SHARE
-
- Close
- Trends in the prevalence of chronic liver disease in theKorean adult population, 1998–2017
-
Park SH, Plank LD, Suk KT, Park YE, Lee J, Choi JH, Heo NY, Park J, Kim TO, Moon YS, Kim HK, Jang HJ, Park HY, Kim DJ
- KMID: 2500385
- Clin Mol Hepatol.
- 2020 Apr;26(2):209-215.
- doi: 10.3350/cmh.2019.0065
Background/Aims: Data on the trends in the prevalence of chronic liver disease (CLD) in Korea are scarce. This study aimed to evaluate whether the CLD prevalence changed between 1998–2001 and... -
- CITED
-
- Close
- SHARE
-
- Close
- Influence of some methylated hepatocarcinogenesis-related genes on the response to antiviral therapy and development of fibrosis in chronic hepatitis C patients
-
Mostafa WS, Al-Dahr MH, Omran DAH, Abdullah Z, Elmasry SH, Ibrahim MN
- KMID: 2501317
- Clin Mol Hepatol.
- 2020 Jan;26(1):60-69.
- doi: 10.3350/cmh.2019.0051
Epigenetics involved in multiple normal cellular processes. Previous research have revealed the role of hepatitis C virus infection in accelerating methylation process and affecting response to treatment in chronic hepatitis... -
- CITED
-
- Close
- SHARE
-
- Close
- An integrated analysis of elbasvir/grazoprevir in Korean patients with hepatitis C virus genotype 1b infection
-
Lee YJ, Heo J, Kim DY, Chung WJ, Tak WY, Kim YJ, Paik SW, Sim E, Kulasingam S, Talwani R, Haber B, Hwang P
- KMID: 2467250
- Clin Mol Hepatol.
- 2019 Dec;25(4):400-407.
- doi: 10.3350/cmh.2019.0006
BACKGROUND/AIMS: In the Republic of Korea, an estimated 231,000 individuals have chronic hepatitis C virus (HCV) infection. The aim of the present analysis was to evaluate the safety and efficacy... -
- CITED
-
- Close
- SHARE
-
- Close
- Comparison of the Clinical Characteristics and Outcomes between Leprosy-Affected Persons in Sorokdo and the General Population Affected by Chronic Hepatitis C in Korea
-
Ahn YH, Park H, Lee MJ, Kim DH, Cho SB, Cho E, Jun CH, Choi SK
- KMID: 2458512
- Gut Liver.
- 2019 Sep;13(5):549-556.
- doi: 10.5009/gnl18432
BACKGROUND/AIMS: Patients with Hansen’s disease are the most vulnerable to hepatitis C. However, no data on the treatment efficacy of direct-acting antiviral agents (DAAs) are available in this group. Therefore,... -
- CITED
-
- Close
- SHARE
-
- Close
- Platelet count is associated with sustained virological response rates in treatments for chronic hepatitis C
-
Jun BG, Park EJ, Lee WC, Jang JY, Jeong SW, Kim YD, Cheon GJ, Cho YS, Lee SH, Kim HS, Lee YN, Kim SG, Kim YS, Kim BS
- KMID: 2457022
- Korean J Intern Med.
- 2019 Sep;34(5):989-997.
- doi: 10.3904/kjim.2017.322
BACKGROUND/AIMS: This study was conducted to clarify the sustained virological response (SVR) prediction ability of baseline and treatment-related factors in patients with chronic hepatitis C virus (HCV) infection. METHODS: This retrospective... -
- CITED
-
- Close
- SHARE
-
- Close
- Daclatasvir and asunaprevir combination therapy for patients with chronic hepatitis C virus genotype 1b infection in real world
-
Oh JY, Kim BS, Lee CH, Song JE, Lee HJ, Park JG, Hwang JS, Chung WJ, Jang BK, Kweon YO, Tak WY, Park SY, Jang SY, Suh JI, Kwak SG
- KMID: 2457309
- Korean J Intern Med.
- 2019 Jul;34(4):794-801.
- doi: 10.3904/kjim.2017.368
BACKGROUND/AIMS: Previous studies have reported a high rate of sustained virologic response (SVR) and a low rate of serious adverse events with the use of daclatasvir (DCV) and asunaprevir (ASV)... -
- CITED
-
- Close
- SHARE
-
- Close
- Direct-acting antivirals-based therapy decreases hepatic fibrosis serum biomarker microfibrillar-associated protein 4 in hepatitis C patients
-
Mölleken , Ahrens M, Schlosser , Dietz J, Eisenacher M, Meyer HE, Schmiegel , Holmskov U, Sarrazin C, Sorensen G, Sitek B, Bracht T
- KMID: 2447250
- Clin Mol Hepatol.
- 2019 Mar;25(1):42-51.
- doi: 10.3350/cmh.2018.0029
BACKGROUND/AIMS: An estimated 80 million people worldwide are infected with viremic hepatitis C virus (HCV). Even after eradication of HCV with direct acting antivirals (DAAs), hepatic fibrosis remains a risk... -
- CITED
-
- Close
- SHARE
-
- Close
- Real-World Clinical Efficacy and Tolerability of Direct-Acting Antivirals in Hepatitis C Monoinfection Compared to Hepatitis C/Human Immunodeficiency Virus Coinfection in a Community Care Setting
-
Gayam V, Hossain MR, Khalid M, Chakaraborty S, Mukhtar O, Dahal S, Mandal AK, Gill A, Garlapati , Ramakrishnaiah S, Mowyad K, Sherigar J, Mansour M, Mohanty S
- KMID: 2427460
- Gut Liver.
- 2018 Nov;12(6):694-703.
- doi: 10.5009/gnl18004
BACKGROUND/AIMS: Limited data exist comparing the safety and efficacy of direct-acting antivirals (DAAs) in hepatitis C virus (HCV) monoinfected and HCV/human immunodeficiency virus (HIV) coinfected patients in the real-world clinic... -
- CITED
-
- Close
- SHARE
-
- Close
- The Efficacy and Safety of Direct-acting Antiviral Treatment for Chronic Hepatitis C Patients: A Single Center Study
-
Park SJ, Kim AR, Choe WH, Kim JH, Yoo BC, Kwon SY
- KMID: 2424111
- Korean J Gastroenterol.
- 2018 Oct;72(4):197-204.
- doi: 10.4166/kjg.2018.72.4.197
BACKGROUND/AIMS: Direct-acting antiviral (DAA) therapy has been shown to achieve a high rate of sustained virologic response (SVR) and favorable outcomes in chronic hepatitis C (CHC) patients. We investigated the... -
- CITED
-
- Close
- SHARE
-
- Close
- Clinical implication of serum uric acid level in pegylated interferon and ribavirin combination therapy for chronic hepatitis C infection
-
Oh IS, Won JW, Kim HJ, Lee HW
- KMID: 2396760
- Korean J Intern Med.
- 2017 Nov;32(6):1010-1017.
- doi: 10.3904/kjim.2016.405
BACKGROUND/AIMS: Combined treatment of pegylated interferon-α (PEG-IFN) and ribavirin (RBV) has long been accepted as the standard treatment for chronic hepatitis C virus (HCV) infection. Many predictive factors for treatment... -
- CITED
-
- Close
- SHARE
-
- Close
- Clinical Characteristics and Treatment Outcome of Peginterferon Plus Ribavirin in Patients Infected with Genotype 6 Hepatitis C Virus in Korea: A Multicenter Study
-
Shin SR, Kim YS, Lim YS, Lee JS, Lee JW, Kim SM, Jeong SH, Sohn JH, Lee MS, Park SH
- KMID: 2412194
- Gut Liver.
- 2017 Mar;11(2):270-275.
- doi: 10.5009/gnl16163
BACKGROUND/AIMS: Because of the limited geographic distribution, there have been insufficient data regarding hepatitis C virus (HCV) genotype 6 in Korea. This study aimed to investigate the clinical characteristics and... -
- CITED
-
- Close
- SHARE
-
- Close
